Effects of levosimendan on circulating proinflammatory cytokines and soluble apoptosis mediators in patients with decompensated advanced heart failure

被引：155

作者：

Parissis, JT

Adamopoulos, S

Antoniades, C

Kostakis, G

Rigas, A

Kyrzopoulos, S

Iliodromitis, E

Kremastinos, D

机构：

[1] Amalia Fleming Hosp, Dept Cardiol 2, Athens, Greece

[2] Onassis Cardiac Surg Ctr, Dept Cardiovasc Med 2, Athens, Greece

来源：

AMERICAN JOURNAL OF CARDIOLOGY | 2004年 / 93卷 / 10期

关键词：

D O I：

10.1016/j.amjcard.2004.01.073

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

This randomized, placebo-controlled trial showed that levosimendan administration causes a significant,reduction of circulating proinflammatory cytokine interleukin-6 and soluble apoptosis mediators, such as soluble Fas and Fas ligand in patients with decompensated heart failure. These immunomodulatory effects may lead to improvement of symptoms and echocardiographic markers of cardiac contractile performance in these patients. (C) 2004 by Excerpta Medica, Inc.

引用

收藏

页码：1309 / 1312

页数：4

相关论文

共 17 条

[1] A glossary of circulating cytokines in chronic heart failure [J].

Adamopoulos, S ;

Parissis, JT ;

Kremastinos, DT .

EUROPEAN JOURNAL OF HEART FAILURE, 2001, 3 (05) :517-526

[2] The calcium sensitizer levosimendan attenuates endotoxin-evoked myocardial dysfunction in isolated guinea pig hearts [J].

Behrends, M ;

Peters, J .

INTENSIVE CARE MEDICINE, 2003, 29 (10) :1802-1807

[3] NEGATIVE INOTROPIC EFFECTS OF CYTOKINES ON THE HEART MEDIATED BY NITRIC-OXIDE [J].

FINKEL, MS ;

ODDIS, CV ;

JACOB, TD ;

WATKINS, SC ;

HATTLER, BG ;

SIMMONS, RL .

SCIENCE, 1992, 257 (5068) :387-389

[4] Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial [J].

Follath, F ;

Cleland, JGF ;

Just, H ;

Papp, JGY ;

Scholz, H ;

Peuhkurinen, K ;

Harjola, VP ;

Mitrovic, V ;

Abdalla, M ;

Sandell, EP ;

Lehtonen, L .

LANCET, 2002, 360 (9328) :196-202

[5] RELATION OF LEFT-VENTRICULAR SHAPE, FUNCTION AND WALL STRESS IN MAN [J].

GOULD, KL ;

LIPSCOMB, K ;

HAMILTON, GW ;

KENNEDY, JW .

AMERICAN JOURNAL OF CARDIOLOGY, 1974, 34 (06) :627-634

[6] Influence of the novel inotropic agent levosimendan on isometric tension and calcium cycling in failing human myocardium [J].

Hasenfuss, G ;

Pieske, B ;

Castell, M ;

Kretschmann, B ;

Maier, LS ;

Just, H .

CIRCULATION, 1998, 98 (20) :2141-2147

[7] Pharmacodynamics and safety of a new calcium sensitizer, levosimendan, and its metabolites during an extended infusion in patients with severe heart failure [J].

Kivikko, M ;

Antila, S ;

Eha, J ;

Lehtonen, L ;

Pentikäinen, PJ .

JOURNAL OF CLINICAL PHARMACOLOGY, 2002, 42 (01) :43-51

[8] Sustained hemodynamic effects of intravenous levosimendan [J].

Kivikko, M ;

Lehtonen, L ;

Colucci, WS .

CIRCULATION, 2003, 107 (01) :81-86

[9] BASIC MECHANISMS IN CONGESTIVE-HEART-FAILURE - RECOGNIZING THE ROLE OF PROINFLAMMATORY CYTOKINES [J].

MANN, DL ;

YOUNG, JB .

CHEST, 1994, 105 (03) :897-904

[10] The clinical relevance of circulating tumor necrosis factor-alpha in acute decompensated chronic heart failure without cachexia [J].

Milani, RV ;

Mehra, MR ;

Endres, S ;

Eigler, A ;

Cooper, S ;

Lavie, CJ ;

Ventura, HO .

CHEST, 1996, 110 (04) :992-995